JOHN VIERLING to Protease Inhibitors
This is a "connection" page, showing publications JOHN VIERLING has written about Protease Inhibitors.
Connection Strength
0.148
-
HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol. 2013 Apr; 108(4):471-5.
Score: 0.096
-
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017 06 01; 376(22):2134-2146.
Score: 0.032
-
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16.
Score: 0.020